These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29635263)

  • 1. Delafloxacin (Baxdela)--a new fluoroquinolone antibiotic.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):49-51. PubMed ID: 29635263
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison table: some antibiotics for MRSA skin and skin structure infections.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e59-e62. PubMed ID: 29635269
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison table: some systemic fluoroquinolones.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e57-e58. PubMed ID: 29635268
    [No Abstract]   [Full Text] [Related]  

  • 4.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections.
    Fernandez J; Hilliard JJ; Morrow BJ; Melton JL; Flamm RK; Barron AM; Lynch AS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5522-8. PubMed ID: 21911568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
    Kaul G; Kapoor E; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Nov; 54(11):657-666. PubMed ID: 30539165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delafloxacin: an improved fluoroquinolone developed through advanced molecular engineering.
    Bassetti M; Righi E; Pecori D; Tillotson G
    Future Microbiol; 2018 Aug; 13():1081-1094. PubMed ID: 29764190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial drugs for community-acquired pneumonia.
    Med Lett Drugs Ther; 2021 Jan; 63(1616):10-14. PubMed ID: 33512346
    [No Abstract]   [Full Text] [Related]  

  • 11. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2020 Aug; 80(12):1247-1258. PubMed ID: 32666425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
    Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
    J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.
    Saravolatz LD; Stein GE
    Clin Infect Dis; 2019 Mar; 68(6):1058-1062. PubMed ID: 30060092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delafloxacin: design, development and potential place in therapy.
    Candel FJ; Peñuelas M
    Drug Des Devel Ther; 2017; 11():881-891. PubMed ID: 28356714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delafloxacin for the treatment of respiratory and skin infections.
    Bassetti M; Della Siega P; Pecori D; Scarparo C; Righi E
    Expert Opin Investig Drugs; 2015 Mar; 24(3):433-42. PubMed ID: 25604710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
    O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
    Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of common respiratory tract infections.
    Med Lett Drugs Ther; 2023 Apr; 65(1674):57-62. PubMed ID: 37039613
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic.
    Li GQ; Bai XG; Li CR; Yang XY; Hu XX; Yuan M; Zhang WX; Lou RH; Guo HY; Jiang JD; You XF
    J Antimicrob Chemother; 2012 Apr; 67(4):955-61. PubMed ID: 22210757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective cohort study of hospitalized adults treated with vancomycin or clindamycin for methicillin-resistant Staphylococcus aureus skin infections.
    Frei CR; Miller ML; Lewis JS; Lawson KA; Peddaiahgari R; Talbert RL
    Clin Ther; 2010 Nov; 32(12):2024-9. PubMed ID: 21118737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.